<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797210</url>
  </required_header>
  <id_info>
    <org_study_id>16-5094</org_study_id>
    <nct_id>NCT02797210</nct_id>
  </id_info>
  <brief_title>Examining the Efficacy of Orbitofrontal Cortex rTMS for Depression</brief_title>
  <acronym>OFC-rTMS</acronym>
  <official_title>Efficacy of Orbital Frontal Cortex Repetitive Transcranial Magnetic Stimulation Magnetic Stimulation in the Treatment of Refractory Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will compare the efficacy of active inhibitory OFC-rTMS to sham OFC-rTMS in major&#xD;
      depression. The trial will include structural and functional MRI, EEG, and behavioral&#xD;
      measures obtained before, during, and after treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>17-Item Hamilton Rating Scale for Depression (HAMD-17)</measure>
    <time_frame>Baseline, after each week of treatment (i.e. after 5 days of treatment) and at 1, 4, and 12 weeks post-treatment.</time_frame>
    <description>Outcome measured by a change in HAMD-17 score from baseline to 2 weeks post-treatment. A 50% improvement in the score is considered a response to rTMS. A final score of &lt;8 is categorized as remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory-II (BDI-II)</measure>
    <time_frame>Daily for 6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>1 week pre- and 1 week post-treatment</time_frame>
    <description>10 min resting-state functional MRI (rs-fMRI) at 3 Tesla (3T)</description>
  </other_outcome>
  <other_outcome>
    <measure>Electroencephalography (EEG)</measure>
    <time_frame>Day 1 (First day of treatment), Day 15, and Day 30 (Final day of treatment)]</time_frame>
    <description>10 min resting-state and task-based (response inhibition, reward sensitivity) acquisitions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Sham then Active Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sham repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then active rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active then Sham Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then sham rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous theta-burst stimulation</intervention_name>
    <arm_group_label>Active then Sham Stimulation</arm_group_label>
    <arm_group_label>Sham then Active Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. are outpatients&#xD;
&#xD;
          2. are voluntary and competent to consent to treatment&#xD;
&#xD;
          3. have a Mini-International Neuropsychiatric Interview (MINI) confirmed diagnosis of&#xD;
             major depressive disorder (MDD), single or recurrent&#xD;
&#xD;
          4. are between the ages of 18 and 65&#xD;
&#xD;
          5. have failed to achieve a clinical response to an adequate dose of an antidepressant&#xD;
             based on an Antidepressant Treatment History Form (ATHF) score of &gt; 3 in the current&#xD;
&#xD;
          6. have a score &gt; 18 on the HAMD-17&#xD;
&#xD;
          7. have had no increase or initiation of any psychotropic medication in the 4 weeks prior&#xD;
             to screening&#xD;
&#xD;
          8. able to adhere to the treatment schedule&#xD;
&#xD;
          9. Pass the TMS adult safety-screening (TASS) questionnaire&#xD;
&#xD;
         10. have normal thyroid functioning based on pre-study blood work.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. have a MINI-International Neuropsychiatric (MINI) confirmed diagnosis of substance&#xD;
             dependence or abuse within the last 3 months&#xD;
&#xD;
          2. have a concomitant major unstable medical illness, cardiac pacemaker or implanted&#xD;
             medication pump&#xD;
&#xD;
          3. have active suicidal intent&#xD;
&#xD;
          4. are pregnant&#xD;
&#xD;
          5. have a lifetime Mini-International Neuropsychiatric Interview (MINI) diagnosis of&#xD;
             bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform&#xD;
             disorder, delusional disorder, or current psychotic symptoms&#xD;
&#xD;
          6. have a MINI diagnosis of obsessive compulsive disorder, post-traumatic stress disorder&#xD;
             (current or within the last year), anxiety disorder (generalized anxiety disorder,&#xD;
             social anxiety disorder, panic disorder), or dysthymia, assessed by a study&#xD;
             investigator to be primary and causing greater impairment than MDD&#xD;
&#xD;
          7. have a diagnosis of any personality disorder, and assessed by a study investigator to&#xD;
             be primary and causing greater impairment than MDD&#xD;
&#xD;
          8. have failed a course of electroconvulsive therapy (ECT) in the current episode or&#xD;
             previous episode&#xD;
&#xD;
          9. have any significant neurological disorder or insult including, but not limited to:&#xD;
             any condition likely to be associated with increased intracranial pressure, space&#xD;
             occupying brain lesion, any history of seizure except those therapeutically induced by&#xD;
             ECT, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis,&#xD;
             significant head trauma with loss of consciousness for greater than or equal to 5&#xD;
             minutes&#xD;
&#xD;
         10. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear&#xD;
             implants, or electrodes) or any other metal object within or near the head, excluding&#xD;
             the mouth, that cannot be safely removed&#xD;
&#xD;
         11. if participating in psychotherapy, must have been in stable treatment for at least 3&#xD;
             months prior to entry into the study, with no anticipation of change in the frequency&#xD;
             of therapeutic sessions, or the therapeutic focus over the duration of the study&#xD;
&#xD;
         12. clinically significant laboratory abnormality, in the opinion of the study&#xD;
             investigator&#xD;
&#xD;
         13. currently (or in the last 4 weeks) take more than lorazepam 2 mg daily (or equivalent)&#xD;
             or any dose of an anticonvulsant due to the potential to limit rTMS efficacy&#xD;
&#xD;
         14. non-correctable clinically significant sensory impairment (i.e., cannot hear well&#xD;
             enough to cooperate with interview).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UHN MRI-Guided rTMS Clinic, Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

